Jaba Recordati, S.A.

Jaba Recordati, S.A. is a Portuguese pharmaceutical company based in Porto Salvo, Portugal, and part of the international Recordati group. It operates in the Portuguese market as a prescription-medicine, over-the-counter and consumer-health business, with a portfolio spanning cardiovascular, urology, central nervous system and oral-health products, as well as generic medicines. The company presents itself as one of the more innovative players in the Portuguese ambulatory market, particularly in cardiovascular and urology, and has launched several innovative medicines in those areas in recent years. On its official Portuguese site, Jaba Recordati markets a mix of prescription and consumer brands. Visible products include Procto-Glyvenol for internal and external haemorrhoids, TransAct LAT plasters for muscle and joint pain, Guronsan for detoxification, Guronenergy as a food supplement with B-complex vitamins, vitamin C and glucoronolactone, and BioGaia as a food supplement with Lactobacillus Reuteri Protectis. The site also provides a store locator covering Portuguese districts and islands, reflecting a retail and pharmacy distribution model. Strategically, Jaba Recordati describes new product launches as its priority, especially in cardiovascular and urology, while also emphasising orphan medicines through the Recordati group's Orphan Europe activity. The company has also highlighted the acquisition of the Spanish company Casen, which is expected to open new market segments, including in Portugal. It continues to strengthen its generics portfolio and plans further prescription launches in CNS and cardiovascular. Organizationally, Jaba Recordati has developed internal initiatives such as the Academia Recordati for staff skills development, the Recordati Care social-responsibility project, and internal and external e-learning tools. It has also used crowdsourcing to refine the positioning of one of its most important products. The Portuguese operation is led by General Director Nelson Ferreira Pires, who has spoken publicly about the company's humanist culture and legacy during Recordati's centenary celebrations.

Jaba Recordati, S.A. is the Portuguese operating company of the Recordati group, an international pharmaceutical group. Its registered and operational base is in Porto Salvo, Portugal. The company is part of Recordati's broader European network and operates under the Recordati Portugal identity on its official website. The Portuguese business has built its position around the ambulatory-care market, with a particular emphasis on cardiovascular and urology. According to its own corporate description, it is considered one of the most innovative companies in the Portuguese ambulatory market and has launched three innovative medicines in cardiovascular and urology over a recent three-year period. It has also stated an intention to enter the central nervous system (CNS) area effectively, and it has launched two OTC products aimed at the oral health of Portuguese consumers, alongside numerous generic medicines. Organizationally, Jaba Recordati has invested in internal capability building through the Academia Recordati, designed to develop the skills of its employees. It has also created Recordati Care, a social-responsibility project, and has been developing internal and external e-learning tools. The company has additionally used a crowdsourcing tool to identify the ideal positioning for one of its most important products, presenting innovation as a theme that runs through the organization at several levels. Looking forward, Jaba Recordati has described new product launches as its strategic priority, especially in cardiovascular and urology. It also values the orphan-medicine area, referencing Recordati's Orphan Europe activity and "life-saving" products. The company has highlighted the acquisition of the Spanish company Casen, which it expects to provide access to new market segments, including in Portugal. In the coming years it expects to launch new prescription products in CNS and cardiovascular, and to continue reinforcing its generics portfolio. The Portuguese operation is led by General Director Nelson Ferreira Pires. In June 2026, during Recordati's centenary celebrations, he gave an interview to Just News in which he discussed the company's humanist culture and the legacy of Jaba Recordati. The centenary itself refers to the 100-year history of the Recordati group, which the Portuguese site marks with the phrase "100 Anos Recordati."

• Recordati group celebrates its centenary, marked on the Portuguese site as "100 Anos Recordati".

• Jaba Recordati launches three innovative medicines in cardiovascular and urology over a recent three-year period.

• Jaba Recordati launches two OTC products for oral health, alongside numerous generic medicines.

• Recordati acquires Spanish company Casen, expected to open new market segments including in Portugal.

• Nelson Ferreira Pires gives a Just News interview during Recordati's centenary, discussing Jaba Recordati's culture and legacy.

Innovative Portuguese pharmaceutical company in ambulatory care, focused on cardiovascular and urology, with growing OTC, generics and orphan-medicine activities.

• Procto-Glyvenol

  Product for external and internal haemorrhoids.

• TransAct LAT

  Plaster for muscle pain and joint pain.

• Guronsan

  Product for detoxification of the body.

• Guronenergy

  Food supplement with B-complex vitamins, vitamin C and glucoronolactone.

• BioGaia

  Food supplement with Lactobacillus Reuteri Protectis.

1. 1Indústria Farmacêutica | Jaba Recordatirecordati.pt
2. 2O nosso Compromisso | Jaba Recordati, S.A.recordati.pt
3. 3Jaba Recordati (Portugal) - Wikidatawikidata.org